Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]DO3A-S01-GCG
- Development stage
- Unknown
- Lead developer
- Antaros Medical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[68Ga]DO3A-S01-GCG (also known as [68Ga]Ga-DO3A-VS-Cys40-Tuna-2 or 68Ga-Tuna-2) is a first-in-class positron emission tomography (PET) radiopharmaceutical imaging tracer that specifically targets the glucagon receptor (GCGR). Developed through a collaboration between Antaros Medical and Sanofi, the tracer consists of a potent GCGR-selective peptide agonist (S01-GCG or Tuna-2) conjugated to a DO3A/DOTA chelator and radiolabeled with gallium-68. It is designed as a target engagement biomarker to non-invasively quantify GCGR occupancy in vivo, particularly to support the clinical development of dual or triple incretin receptor agonists (such as GLP-1/GCG dual agonists) for metabolic disorders. The tracer has been evaluated in Phase I clinical studies in individuals with type 2 diabetes and obesity to assess the receptor occupancy of therapeutic candidates like SAR425899.
- Other names
- 68Ga-DO3A-GCG-S0168Ga-DO3A-VS-Tuna-268Ga-Tuna-2[68Ga]DO3A-Tuna-2[68Ga]DO3A-VS-Cys40-Tuna-2[68Ga]Ga-DO3A-S01-GCG[68Ga]Ga-DO3A-Tuna-2[68Ga]Ga-DO3A-VS-Cys40-Tuna-2
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on [68Ga]DO3A-S01-GCG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]DO3A-S01-GCG.